Physician profile
Ronald Lang
NPI 1639230550
$1,783.17
in general payments reported to CMS, 2019-2025
22 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $55.48 · 2021: $251 · 2022: $491 · 2023: $364 · 2024: $183 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.71 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $422.65 | 2021-2024 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $301.76 | 2021-2024 | |
| Amgen INC. | $156.86 | 2021-2025 | Evenity, Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $130.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $86.63 | 2025 | |
| Horizon Therapeutics Plc | $82.26 | 2022-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $78.78 | 2024-2025 | Benlysta, Jesduvroq |
| Global Blood Therapeutics, INC. | $60.79 | 2021 | |
| Viiv Healthcare Company | $58.33 | 2023 | Apretude |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.09 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $56.01 | 2020-2021 | |
| Outset Medical INC | $47.59 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.56 | 2021-2022 | |
| Cepheid | $32.00 | 2025 | Genexpert |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.94 | 2025 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.04 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.63 | 2022 | |
| Travere Therapeutics, INC. | $23.09 | 2023 | |
| Exact Sciences Corporation | $22.23 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $20.33 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $16.92 | 2021 | |
| Genzyme Corporation | $15.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.